Lee's Pharmaceutical Holdings Ltd. engages in the development, manufacture, and sale of pharmaceutical products. The company employs 1,022 full-time employees The company went IPO on 2002-07-15. The firm operates its business through two segments. The Imported Products segment is engaged in the sale of imported products. Its imported products include Keyan injection, Fipril oral solution and others. The Proprietary Products segment is engaged in the manufacture and sale of self-developed products. Its R&D products include Resilicon Tablets, ADASUVE Inhalation Powder and others. The firm's medicines cover the fields of cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology. The firm mainly operates its business in mainland China, Hong Kong and Taiwan.